Innovative Pediatric Therapy JelikaLite is developing Cognilum, a home-based non-invasive therapy platform combining wearable near-infrared light technology with an AI-driven tracking system. This positions the company to target clinicians and therapists seeking scalable at-home solutions to support pediatric neurological health and autism symptom reduction.

Early Access Opportunity Recent announcements point to an early access waitlist for the autism therapy device, indicating a potential pre-launch pipeline. Sales teams can engage early adopters, therapists, and institutions interested in cutting-edge neurotherapy tools and clinical evaluation programs.

Cost Reduction Narrative Cognilum emphasizes potential to lower lifelong costs related to special education and residential care by enabling better integration and outcomes. This can be leveraged when approaching payers, government programs, and school districts to frame a value-based purchasing case.

Strategic Partnerships Past collaboration with Brain Scientific highlights appetite for partnerships in neurology-focused hardware and software. Rep outreach can explore co-development, clinical trials, and co-marketing arrangements to accelerate validation and adoption.

Market Positioning With a focused product in pediatric neurological health and a revenue range in the low millions, JelikaLite operates in a competitive, wellness-technology space alongside firms like Omnilux and LightStim. This presents an opportunity to position Cognilum as a cost-effective, home-based alternative or complement to existing in-clinic therapies.